title: Safety of bisphosphonates in the treatment of osteoporosis.
abstract: In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).
authors.affiliation: School of Medicine, Creighton University, Omaha, Nebraska, USA.
authors.forename: Robert R
authors.initials: RR
authors.lastname: Recker
authors.forename: E Michael
authors.initials: EM
authors.lastname: Lewiecki
authors.forename: Paul D
authors.initials: PD
authors.lastname: Miller
authors.forename: James
authors.initials: J
authors.lastname: Reiffel
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D002908:Chronic Disease; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D009140:Musculoskeletal Diseases / Q000139:chemically induced; D010024:Osteoporosis / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates